📣 Try out the NEW Gateway to Research and let us know what you think.

We're looking for users to test the new service during August and September and share their feedback. Express your interest by completing this short form.

Value Assessment and Quantitative Benefit-Risk Modelling of Biosimilar Infliximab for Crohn's Disease. (2019)

First Author: Catt H

Attributed to: Renewal of the Network of Hubs for Trials Methodology Research. funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1007/s40273-019-00826-0

PubMed Identifier: 31372948

Publication URI: http://europepmc.org/abstract/MED/31372948

Type: Journal Article/Review

Volume: 37

Parent Publication: PharmacoEconomics

Issue: 12

ISSN: 1170-7690